RE:RE:RE:RE:ONCY posts Q2'23 Financials & mBC intentNoteable, most would agree with you re AA, especially because of the limited therapies available to treat panc. Also, AA could be the catalyst to finally attract both retail and possible buyout or partnership with BP. However, without this event, it will be more of the same from ONCY management. They obviously don't have anywhere near the resources to do 2 PIII trials, which means more dilution will be a certainty. The current action on the sp would suggest the market isn't enthusiastic, at least yet, with a FDA AA. The burning question is do we need this to finally attract a BP. The fireside chat barely mentioned partnership or ongoing talks with a BP.